Stay updated on Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial
Sign up to get notified when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.

Latest updates to the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page
- Check7 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check14 days agoChange DetectedThe web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.SummaryDifference1%
- Check22 days agoNo Change Detected
- Check29 days agoNo Change Detected
- Check43 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2, indicating a revision in the content.SummaryDifference0.1%
- Check58 days agoChange DetectedThe webpage has been updated to reflect a new version of a clinical study on metastatic breast cancer, including a change in the principal investigator and the addition of specific treatment details. The study now emphasizes the use of Pembrolizumab in combination with HER2 Bispecific Antibody Armed Activated T-Cell infusions.SummaryDifference45%
- Check65 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check72 days agoChange DetectedThe web page has updated its version from v2.14.2 to v2.14.3 and changed the date from November 2024 to March 2025.SummaryDifference0.4%
Stay in the know with updates to Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Her2-BATS and Pembrolizumab in Metastatic Breast Cancer Clinical Trial page.